Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares Silver Trust (SLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares Silver Trust — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while iShares Silver Trust trades at $52.53. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| ACAD | SLV | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $105.57 |
52-Week Low | $20.06 | $33.00 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SLV, the iShares Silver Trust ETF, trades at $54.46, down 1.02% on the day, reflecting ongoing volatility in silver prices. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent news highlights silver's 50% decline from January peaks but potential for a rebound amid industrial demand and inflation hedging. Financial ratios are not applicable as this is a commodity ETF tracking physical silver.
The outlook for SLV hinges on silver's dual role as an industrial metal and inflation hedge, with risks including Federal Reserve policy shifts and geopolitical tensions. Analysts see potential for price recovery if macroeconomic conditions support precious metals, but near-term volatility remains high due to rate hike expectations and dollar strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
